FrancophonIA/ELRC3.0 huggingface dataset:
English: Your doctor may decide to start your treatment with 20 mg twice a day for two weeks before increasing the dose to 40 mg twice a day.
Slovenian: Vaš zdravnik se lahko odloči za začetek vašega zdravljenja z 20 mg dvakrat na dan za dva tedna pred zvišanjem odmerka na 40 mg dvakrat na dan.
English: Your doctor should decide whether you can take YENTREVE with other medicines.
Slovenian: Vaš zdravnik se mora odločiti, ali lahko jemljete zdravilo YENTREVE z drugimi zdravili.
English: Please tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.
Slovenian: Obvestite svojega zdravnika ali farmacevta, če jemljete, ste pred kratkim jemali, ali pa boste morda začeli jemati katerokoli zdravilo, tudi če ste ga dobili brez recepta.
English: In animal studies, increased levels of 5-HT and NE in the sacral spinal cord, lead to increased urethral tone via enhanced pudendal nerve stimulation to the urethral striated sphincter muscle only during the storage phase of the micturition cycle.
Slovenian: V študijah na živalih povišane koncentracije 5-HT in NA v sakralni hrbtenjači povzročijo zvišan tonus sečnice prek ojačane stimulacije pudendalnega živca prečnoprogaste sfinktrske mišice sečnice, ki se pojavlja samo med shranjevalno fazo mikcijskega cikla.
English: • Yentreve may cause effects that you may not be aware of, such as increases in liver enzymes or blood levels of potassium, creatine phosphokinase, sugar, or cholesterol
Slovenian: • Yentreve lahko povzroči tudi neželene učinke, ki se jih morda ne zavedate, kot povišanje jetrnih encimov ali krvnega nivoja kalija, kreatinske fosfokinaze, sladkorja ali holesterola.
English: • Tell your doctor if you become pregnant, or you are trying to become pregnant, while you are taking YENTREVE.
Slovenian: • Obvestite svojega zdravnika, če zanosite ali poskušate zanositi, medtem ko jemljete zdravilo YENTREVE.
English: Date of first authorisation: 11 August 2004 Date of latest renewal: 24 June 2009
Slovenian: Datum podaljšanja dovoljenja za promet: 24. junij 2009
English: If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Slovenian: Nosečnost in dojenje Če ste noseči ali dojite, menite, da bi lahko bili noseči ali načrtujete zanositev, se posvetujte se s svojim zdravnikom ali s farmacevtom, preden vzamete to zdravilo.
English: Elderly Caution should be exercised when treating the elderly.
Slovenian: Starejši Pri zdravljenju starejših je potrebna posebna previdnost.
English: Do not stop taking YENTREVE, or change your dose, without talking to your doctor.
Slovenian: Ne prenehajte jemati zdravila YENTREVE in ne spreminjajte odmerka, ne da bi se posvetovali s svojim zdravnikom.
English: Using a global improvement scale (PGI), significantly more women using duloxetine considered their symptoms of stress incontinence to be improved with treatment compared with women using placebo (64.6% versus 50.1%, p<0.001).
Slovenian: Glede na lestvico splošnega izboljšanja (PGI) je značilno več žensk, ki so jemale duloksetin, ocenilo svoje simptome stresne inkontinence za izboljšane z zdravljenjem, v primerjavi z ženskami, ki so prejemale placebo (64,6 % v primerjavi s 50,1 %, p < 0,001).
English: Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.
Slovenian: Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu
English: Studies in juvenile rats reveal transient effects on neurobehaviour, as well as significantly decreased body weight and food consumption; hepatic enzyme induction; and hepatocellular vacuolation at 45 mg/kg/day.
Slovenian: Študije na mladih podganah kažejo na prehodne učinke na nevrološki vedenjski vzorec ter na znatno zmanjšanje telesne teže in uživanje hrane, indukcijo jeternih encimov in hepatocelularno vakuolacijo pri 45 mg/kg/dan.
English: • suicidal behaviour, suicidal thoughts, mania (over activity, racing thoughts and decreased need for sleep), hallucinations, aggression and anger
Slovenian: • samomorilno vedenje, samomorilske misli, manija (prevelika aktivnost, bežeče misli in zmanjšana potreba po spanju), halucinacije, agresivnost in jeza
English: Although YENTREVE is not indicated for the treatment of depression, its active ingredient (duloxetine) also exists as an antidepressant medicinal product.
Slovenian: Čeprav zdravilo YENTREVE ni indicirano za zdravljenje depresije, njegova učinkovina (duloksetin) obstaja tudi kot antidepresiv.
English: Elimination: The elimination half-life of duloxetine ranges from 8 to 17 hours (mean of 12 hours).
Slovenian: Izločanje: Razpolovni čas izločanja duloksetina po peroralnem odmerku je od 8 do 17 ur (povprečno 12 ur).
English: Patients with a history of suicide-related events or those exhibiting a significant degree of suicidal thoughts prior to commencement of treatment are known to be at a greater risk of suicidal thoughts or suicidal behaviour, and should receive careful monitoring during treatment.
Slovenian: Znano je, da pri bolnikih s samomorom povezanimi dogodki v anamnezi, ali bolnikih, ki kažejo znatno stopnjo samomorilne miselnosti pred uvedbo zdravljenja, obstaja večje tveganje za samomorilne misli ali poskusov samomora in jih je treba med zdravljenjem skrbno spremljati.
English: The primary efficacy measures were Incontinence Episode Frequency (IEF) from diaries and an incontinence specific quality of life questionnaire score (I-QOL).
Slovenian: Primarni merili učinkovitosti sta bili pogostnost inkontinenčnih epizod (Incontinence Episode Frequency, IEF) iz dnevnikov zdravljenja ter število točk po vprašalniku o kakovosti življenja, specifičnem za inkontinenco (I-QOL).
English: Polyvinylchloride (PVC), polyethylene (PE), and polychlorotrifluoroethylene (PCTFE) blister sealed with an aluminium foil.
Slovenian: Pretisni omoti iz polivinilklorida (PVC), polietilena (PE) in poliklorotrifluoroetilena (PCTFE), zaprti z aluminijasto folijo.
English: When stopping treatment with YENTREVE the dose should be gradually reduced over a period of at least one to two weeks in order to reduce the risk of withdrawal reactions (see sections 4.4 and 4.8).
Slovenian: Ob prenehanju zdravljenja z zdravilom YENTREVE je treba odmerek zdravila v obdobju najmanj enega do dveh tednov postopoma zmanjševati, da zmanjšamo tveganje za pojav odtegnitvenih reakcij (glejte poglavji 4.4 in 4.8).
English: • If you take YENTREVE near the end of your pregnancy there is an increased risk of excessive vaginal bleeding shortly after birth, especially if you have a history of bleeding disorders.
Slovenian: • Če zdravilo YENTREVE jemljete proti koncu nosečnosti, obstaja povečano tveganje za čezmerno krvavitev iz nožnice kmalu po porodu, sploh če ste v preteklosti že imeli motnje strjevanja krvi.
English: • grinding or clenching the teeth, feeling disorientated, lack of motivation, difficulty or failure to experience orgasm, unusual dreams
Slovenian: • škrtanje ali drgetanje z zobmi, občutek zmedenosti, pomanjkanje motivacije, težave ali nezmožnost doseči orgazem, nenavadne sanje
English: YENTREVE is available in 2 strengths: 20 and 40 mg.
Slovenian: Zdravilo YENTREVE je na voljo v dveh jakostih: 20 in 40 mg.
English: • feeling the heart pumping in the chest, fast and/or irregular heart beat
Slovenian: • občutek bitja srca v prsih, hitro in/ali nepravilno bitje srca
English: Combining YENTREVE with a pelvic floor muscle training (PFMT) programme may be more effective than either treatment alone.
Slovenian: Kombiniranje jemanja zdravila YENTREVE s programom treninga mišic medeničnega dna (pelvic floor muscle training,PFMT) je lahko bolj učinkovito, kot če metodi zdravljenja uporabljamo posamezno.
English: Duloxetine is used under different trademarks in several indications (treatment of diabetic neuropathic pain, major depressive disorder, generalised anxiety disorder and stress urinary incontinence).
Slovenian: Duloksetin se pod različnimi imeni uporablja za več indikacij (zdravljenje bolečine zaradi diabetične nevropatije, velikih depresivnih motenj, generalizirane anksiozne motnje in stresne urinske inkontinence).
English: Component of a multipack, can't be sold seperately.
Slovenian: Del večjega pakiranj, ni za ločeno prodajo.
English: Inducers of CYP1A2: Population pharmacokinetic studies analyses have shown that smokers have almost 50% lower plasma concentrations of duloxetine compared with non-smokers.
Slovenian: Induktorji CYP1A2: analize študij populacijske farmakokinetike so pokazale, da imajo kadilci v primerjavi z nekadilci skoraj za 50 % nižje plazemske koncentracije duloksetina.
English: The absolute oral bioavailability of duloxetine ranged from 32% to 80% (mean of 50%).
Slovenian: Absolutna peroralna biološka uporabnost duloksetina zavzema vrednosti od 32 do 80 % (povprečje
English: Studies in animals have shown reproductive toxicity at systemic exposure levels (AUC) of duloxetine lower than the maximum clinical exposure (see section 5.3).
Slovenian: Študije na živalih so pokazale reproduktivno toksičnost pri nižjih ravneh sistemskega izpostavljanja (AUC) duloksetinu kot je največja klinična izpostavitev (glejte poglavje 5.3).
English: The efficacy of duloxetine 40 mg given twice daily in the treatment of SUI was established in four double-blind, placebo-controlled studies that randomised 1913 women (22 to 83 years) with SUI; of these, 958 patients were randomised to duloxetine and 955 to placebo.
Slovenian: Učinkovitost 40 mg duloksetina, danega dvakrat dnevno, pri zdravljenju SUI je bila ugotovljena v štirih dvojno slepih, s placebom kontroliranih študijah, v katerih so naključno razporedili 1913 žensk (22 do 83 let) s SUI; od teh jih je bilo 958 naključno razporejenih v skupino zdravljenja z duloksetinom in 955 v skupino, ki je prejemala placebo.
English: If concomitant treatment with duloxetine and other serotonergic agents that may affect the serotonergic and/or dopaminergic neurotransmitter systems in clinically warranted, careful observation of the patient is advised, particularly during treatment initiation and dose increases.
Slovenian: Če je sočasno zdravljenje z duloksetinom in drugimi serotonergičnimi zdravili, ki lahko vplivajo na serotonergične in/ali dopaminergične nevrotransmiterske sisteme klinično upravičeno, je priporočljivo bolnika skrbno nadzirati, še posebej med uvajanjem zdravljenja in pri zviševanju odmerkov.
English: The requirements for submission of periodic safety update reports for this medicinal product are in accordance with the requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and any subsequent updates published on the European medicines web-portal.
Slovenian: Zahteve glede predložitve redno posodobljenega poročila o varnosti zdravila za to zdravilo so določene v seznamu referenčnih datumov Unije (seznamu EURD), opredeljenem v členu 107c(7)
English: YENTREVE is indicated in adults.
Slovenian: Zdravilo YENTREVE je indicirano za zdravljenje odraslih.
English: • If you take YENTREVE near the end of your pregnancy, your baby might have some symptoms when it is born.
Slovenian: • Če zdravilo YENTREVE jemljete proti koncu nosečnosti, se lahko po rojstvu pri vašem otroku pojavijo nekateri simptomi.
English: In a clinical trial, adverse events seen on abrupt treatment discontinuation occurred in approximately 44% of patients treated with YENTREVE and 24% of patients taking placebo.
Slovenian: V kliničnih preskušanjih so se neželeni učinki ob nenadni prekinitvi zdravljenja pojavili pri približno 44 % bolnic, ki so jemale zdravilo YENTREVE in pri 24 % bolnic, ki so dobivale placebo.
English: Stress urinary incontinence is a medical condition in which patients have accidental loss or leakage of urine during physical exertion or activities such as laughing, coughing, sneezing, lifting, or exercise.
Slovenian: Stresna urinska inkontinenca je zdravstveno stanje, pri katerem bolnikom nezgodno uhaja urin med telesnim naporom ali dejavnostmi, kot so smeh, kašljanje, kihanje, dviganje ali telesna vadba.
English: Use in children and adolescents under 18 years of age YENTREVE should not be used in the treatment of children and adolescents under the age of 18 years.
Slovenian: Uporaba pri otrocih in mladostnikih, mlajših od 18 let Zdravila YENTREVE pri otrocih in mladostnikih, mlajših od 18 let, ne smemo uporabljati.
English: You should take extra care if you drink alcohol while taking YENTREVE.
Slovenian: Bodite posebej previdni, če med jemanjem zdravila YENTREVE pijete alkohol.
English: YENTREVE may cause a sensation of restlessness or an inability to sit or stand still.
Slovenian: Zdravilo YENTREVE lahko povzroči občutek nemira ali nezmožnosti sedenja ali stanja pri miru.
English: Also, the long-term safety effects concerning growth, maturation, and cognitive and behavioural development of YENTREVE in this age group have not yet been demonstrated.
Slovenian: dozorevanja in kognitivnega ter vedenjskega razvoja v tej starostni skupini tudi še niso bili ugotovljeni.
English: Medicines like Yentreve (so called SSRIs/SNRIs) may cause symptoms of sexual dysfunction (see section 4).
Slovenian: Zdravila, kot je zdravilo YENTREVE (t. i. SSRI/SNRI), lahko povzročijo simptome spolne disfunkcije (glejte poglavje 4).
English: Also, you should know that patients under 18 have an increased risk of side-effects such as suicide attempt, suicidal thoughts and hostility (predominantly aggression, oppositional behaviour and anger) when they take this class of medicines.
Slovenian: Prav tako se moramo zavedati, da imajo bolniki, mlajši od 18 let, večje tveganje za neželene učinke, denimo poskus samomora, samomorilne misli in sovražnost (zlasti nasilnost, nasprotovalno vedenje in jezo),
English: YENTREVE is believed to work by increasing the strength of the muscle that holds back urine when you laugh, sneeze, or perform physical activities.
Slovenian: Ugotovili so, da zdravilo YENTREVE deluje tako, da poveča moč mišice, ki zadržuje urin, ko se smejite, kihate ali ste telesno dejavni.
English: Effects of other medicinal products on duloxetine
Slovenian: Učinki drugih zdravil na duloksetin
English: Fluvoxamine (100 mg once daily), a potent inhibitor of CYP1A2, decreased the apparent plasma clearance of duloxetine by about 77% and increased AUC0-t 6-fold.
Slovenian: Fluvoksamin (100 mg enkrat dnevno), močan zaviralec CYP1A2, je znižal očitni plazemski očistek duloksetina za približno 77 % in povečal AUC0-t za 6-krat.
English: Do not store above 30° C.
Slovenian: Shranjujte pri temperaturi do 30 °C.
English: Detailed information on this medicine is available on the European Medicines Agency (EMA) web site: http://www.ema.europa.eu
Slovenian: DATUM ZADNJE REVIZIJE BESEDILA Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila (European Medicines Agency; EMA): http://www.ema.europa.eu
English: Combined therapy (duloxetine + PFMT) showed greater improvement in both pad use and condition-specific quality of life measures than YENTREVE alone or PFMT alone.
Slovenian: Kombinirano zdravljenje (duloksetin + PFMT) je pokazalo večje izboljšanje tako pri porabi predlog kot pri merilih kakovosti življenja, specifičnih za stanje, kot samo zdravilo YENTREVE ali samo PFMT.
English: The data analysis of four 12-week, placebo-controlled clinical trials in patients with SUI, including 958 duloxetine-treated and 955 placebo-treated patients, showed that the onset of the reported adverse events typically occurred in the first week of therapy.
Slovenian: Analiza podatkov štirih 12-tedenskih, s placebom kontroliranih kliničnih preskušanj pri bolnicah s SUI, vključno z 958 bolnicami, ki so prejemale duloksetin in 955 bolnicami, ki so prejemale placebo, je pokazala, da so se poročani neželeni učinki značilno pojavili v prvem tednu zdravljenja.
English: In the 12 week acute phase of three clinical trials of duloxetine in patients with diabetic neuropathic pain, small but statistically significant increases in fasting blood glucose were observed in duloxetinetreated patients.
Slovenian: V 12 tednov trajajoči akutni fazi treh kliničnih preskušanj duloksetina pri bolnikih z bolečino zaradi diabetične nevropatije so pri bolnikih, zdravljenih z duloksetinom, opažali majhna, a statistično značilna povišanja koncentracij glukoze v krvi na tešče.
English: If you forget to take YENTREVE
Slovenian: Če ste pozabili vzeti zdravilo YENTREVE
English: The recommended dose of YENTREVE is 40 mg twice daily without regard to meals.
Slovenian: Priporočeni odmerek zdravila YENTREVE je 40 mg dvakrat dnevno ne glede na obroke.
English: If you are depressed and/or have anxiety disorders you can sometimes have thoughts of harming or killing yourself.
Slovenian: Pri bolnikih z depresijo in/ali anksiozno motnjo se občasno lahko pojavijo misli na samopoškodovanje ali samomor.
English: Caution is required in patients at increased risk for hyponatraemia, such as elderly, cirrhotic, or dehydrated patients or patients treated with diuretics.
Slovenian: Previdnost je potrebna pri bolnicah z večjim tveganjem za hiponatremijo; denimo pri starejših, bolnicah s cirozo, dehidriranih bolnicah ali bolnicah, ki jemljejo diuretike.
English: • difficulty to start urinating, painful urination, needing to pass urine during the night, frequent urination, abnormal urine odour
Slovenian: • težave z začetkom uriniranja, boleče uriniranje, potreba po nočnem odvajanju urina, pogosto uriniranje, nenormalen vonj urina
English: The co-administration of duloxetine (40 mg twice daily) increases steady state AUC of tolterodine (2 mg twice daily) by 71 %, but does not affect the pharmacokinetics of its active 5-hydroxyl metabolite and no dosage adjustment is recommended.
Slovenian: Sočasno dajanje duloksetina (40 mg dvakrat dnevno) poveča AUC tolterodina (2 mg dvakrat dnevno) v stanju dinamičnega ravnovesja za 71 %, ne vpliva pa na farmakokinetiko njegovega aktivnega 5-hidroksi presnovka, zato ne priporočamo prilagajanja odmerjanja.
English: Female rats receiving duloxetine before and during mating and early pregnancy had a decrease in maternal food consumption and body weight, oestrous cycle disruption, decreased live birth indices and progeny survival, and progeny growth retardation at systemic exposure levels estimated to be at the most at maximum clinical exposure (AUC).
Slovenian: Podganje samice, ki so prejemale duloksetin pred in med parjenjem ter zgodnjo brejostjo, so kazale zmanjšano porabo hrane in znižanje telesne mase pri materah, motnje estrus ciklusa, zmanjšano število živorojenih in slabše preživetje potomcev ter zastoj rasti potomcev pri sistemskih izpostavitvah, ocenjenih kot največ maksimalna klinična izpostavitev (AUC).
English: The main ingredient of YENTREVE, duloxetine, is used in other medicines for other conditions:
Slovenian: Duloksetin, glavna učinkovina zdravila YENTREVE se uporablja v drugih zdravilih za zdravljenje drugih bolezni:
English: Each capsule of YENTREVE contains pellets of duloxetine hydrochloride with a covering to protect them from stomach acid.
Slovenian: Vsaka kapsula zdravila YENTREVE vsebuje pelete duloksetinijevega klorida z oblogo za zaščito pred želodčno kislino.
English: • large pupils (the dark centre of the eye), problems with eyesight, eyes feel dry
Slovenian: • večje zenice (temni osrednji del očesa), motnja vida, občutek suhih oči
English: The pharmacokinetics of duloxetine in patients who are poor metabolisers with respect to CYP2D6 has not been specifically investigated.
Slovenian: Farmakokinetike duloksetina pri bolnikih, ki imajo omejeno presnovo s CYP2D6, niso posebej preiskovali.
English: Antacids and H2 antagonists: Co-administration of YENTREVE with aluminium- and magnesiumcontaining antacids or with famotidine had no significant effect on the rate or extent of duloxetine absorption after administration of a 40 mg oral dose.
Slovenian: Antacidi in antagonisti H2: sočasno dajanje zdravila YENTREVE z antacidi, vsebujočimi aluminij in magnezij, ali s famotidinom ni imelo pomembnega učinka na hitrost ali obseg absorpcije duloksetina po dajanju 40 mg peroralnega odmerka.
English: Absorption: Duloxetine is well absorbed after oral administration with a Cmax occurring 6 hours post dose.
Slovenian: Absorpcija: Duloksetin se po peroralnem dajanju dobro absorbira s pojavom Cmax 6 ur po odmerjanju.
English: 10Estimated frequency based on placebo-controlled clinical trials.
Slovenian: 10 Ocenjena pogostnost na podlagi kliničnih preskušanj, nadzorovanih s placebom.
English: Inhibitors of CYP1A2: Because CYP1A2 is involved in duloxetine metabolism, concomitant use of YENTREVE with potent inhibitors of CYP1A2 is likely to result in higher concentrations of duloxetine.
Slovenian: Zaviralci CYP1A2: ker je CYP1A2 vpleten v presnovo duloksetina, je verjetno, da bo sočasna uporaba zdravila YENTREVE z močnimi zaviralci CYP1A2 povzročila višje koncentracije duloksetina.
English: Supra-ventricular arrhythmia, mainly atrial fibrillation6
Slovenian: Srčne bolezni palpitacije tahikardija supraventrikularna aritmija, zlasti atrijska fibrilacija6
English: • Make sure your midwife and/or doctor knows you are on YENTREVE.
Slovenian: • Svoji medicinski sestri, babici in/ali zdravniku povejte, da jemljete zdravilo YENTREVE.
English: Other medicines and YENTREVE
Slovenian: Druga zdravila in zdravilo YENTREVE
English: If you have further questions on the use of this medicine, ask your doctor or pharmacist.
Slovenian: Če imate dodatna vprašanja o uporabi zdravila, se posvetujte z zdravnikom ali s farmacevtom.
English: YENTREVE hard gastro-resistant capsules contain sucrose.
Slovenian: YENTREVE trde gastrorezistentne kapsule vsebujejo saharozo.
English: Hyponatraemia has been reported when administering YENTREVE, including cases with serum sodium lower than 110 mmol/l.
Slovenian: Ob dajanju zdravila YENTREVE so poročali o hiponatriemiji, vključno s primeri, ko je bila serumska koncentracija natrija pod 110 mmol/l.
English: If you stop taking YENTREVE
Slovenian: Če ste prenehali jemati zdravilo YENREVE
English: The initiation of treatment with YENTREVE is contraindicated in patients with uncontrolled hypertension that could expose patients to a potential risk of hypertensive crisis (see sections 4.4 and
Slovenian: Uvedba zdravljenja z zdravilom YENTREVE je kontraindicirana pri bolnicah z nenadzorovano hipertenzijo, ki lahko izpostavi bolnice možnemu tveganju za hipertenzivno krizo (glejte poglavje 4.4 in 4.8).
English: YENTREVE should not be used in combination with CYP1A2 inhibitors, like fluvoxamine, ciprofloxacin or enoxacin since the combination results in elevated plasma concentrations of duloxetine (see section 4.5).
Slovenian: Zdravila YENTREVE ne smemo uporabljati v kombinaciji z zaviralci CYP1A2, kot so fluvoksamin, ciprofloksacin ali enoksacin, ker kombinacija povzroči povišane plazemske koncentracije duloksetina (glejte poglavje 4.5).
English: A meta-analysis of placebocontrolled clinical trials of antidepressant medicinal products in psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants compared to placebo in patients less than 25 years old.
Slovenian: Metaanaliza s placebom nadzorovanih kliničnih preskušanj antidepresivov pri odraslih bolnikih s psihiatričnimi motnjami je pokazala, da pri bolnikih, mlajših od 25 let, pri uporabi antidepresivov obstaja večje tveganje za pojav samomorilnega vedenja kot pri uporabi placeba.
English: YENTREVE and Prior Continence Surgery: There are limited data that suggest that the benefits of YENTREVE are not diminished in women with stress urinary incontinence who have previously undergone continence surgery.
Slovenian: Zdravilo YENTREVE in predhodno kirurško zdravljenje inkontinence: omejeni podatki kažejo, da koristi zdravila YENTREVE pri bolnicah s stresno urinsko inkontinenco, ki so bile predhodno operirane zaradi inkontinence, niso zmanjšane.